Examples of using Evra in English and their translations into Italian
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
-
Official/political
CONT-002 EVRA.
As the EVRA transdermal patch contains similar hormones to those used in combined birth control pills,
It is possible that the risk of blood clots in the legs and/ or lungs with EVRA is more than the risk with combined birth control pills.
Using a combined hormonal contraceptive such as EVRA increases your risk of developing a blood clot compared with not using one.
EVRA is available in the following pack sizes:
EVRA contains two types of hormones:• norelgestromin• ethinyl estradiol Because it contains two hormones, EVRA is called a‘ combined hormonal contraceptive.
especially if your periods were not regular before you started using EVRA.
the suitability of EVRA should be discussed with the woman.
Studies have suggested that the incidence of VTE in women who used EVRA is up to 2-fold higher than in users of CHCs that contain levonorgestrel.
according the recommended regimen, a cause other than EVRA should be considered.
Studies conducted to examine the dermal effect of EVRA indicate this system has no potential to produce sensitisation
If you have an upset stomach• The amount of hormones you get from EVRA should not be affected by being sick(vomiting)
The decision to prescribe EVRA should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism(VTE), and how the risk of VTE with EVRA compares with other CHCs see sections 4.3 and 4.4.
To prevent interference with the adhesive properties of EVRA, no creams, lotions or powders should be applied to the skin area where the EVRA transdermal patch is to be applied.
If EVRA remains even partly detached: for less than one day(up to 24 hours): it should be re-applied to the same place or replaced with a new EVRA transdermal patch immediately.
mentioned below is present, the benefits of the use of EVRA should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using EVRA.
the woman should be advised to contact her doctor to determine whether the use of EVRA should be discontinued.
Although only 10-20% of the variability in pharmacokinetic data can be explained by weight(see section 5.2), the greater proportions of pregnancies among women at or above 90 kg was statistically significant and indicates the EVRA is less effective in these women.
If you switch from the mini-pill to EVRA• You may start EVRA any day after stopping the mini-pill• The first day after stopping the mini-pill,
Always use EVRA exactly as described in this leaflet.•